A Phase 2 interventional study of AZD0292 and Placebo in Bronchiectasis With Pseudomonas Aeruginosa Colonization, sponsored by AstraZeneca. Recruiting at 40 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by AstraZeneca · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Bronchiectasis with a site in China — 35 open to participants now, 38 under way, 4 of them phase 3. Bronchiectasis · China.
Among the 84 studies in Bronchiectasis with a site in China, this one is the 35th largest by planned enrollment of the 50 interventional ones that give a count, is one of 9 that started in 2026, is one of 10 in phase 2, reaches primary completion later than 28 of the 37 other live ones, and was the 76th registered.
404 studies on the registry are indexed under Bronchiectasis; 125 are open to participants now.
Browse Bronchiectasis studies →35 of the 84 studies in Bronchiectasis with a site in China are open now. Recruiting first, the newest first:
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–45 · Healthy volunteers
Shanghai Pulmonary Hospital, Shanghai, China · Sites in China
Ages 18+
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70 · Healthy volunteers
First Affiliated Hospital of Ningbo University · Sites in China
Ages 18–80
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 93 Bronchiectasis studies recruiting now, 50 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 12 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 12 · Phase 3 7 · Phase 4 14
First in 2011; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 84 is above the median of 60 across 263 interventional studies indexed under Bronchiectasis.
Median enrollment 120 across the 50 interventional studies, 300 across the 34 observational. Of the 23 that completed or were terminated, 8 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 84 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 6 studies filed under Bronchiectasis — fewer than ten, so there is no comparison to draw.
15 of the studies in Bronchiectasis with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660992Phase 3Haisco Pharmaceutical Group Co., Ltd.A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis | 2026-11-28 |
| NCT06872892Phase 3Boehringer IngelheimThe AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis | 2027-06-15 |
| NCT07915024Haisco Pharmaceutical Group Co., Ltd.Phase 1 Study to Assess the Effects of HSK31858 on the QT/QTc Interval in Healthy Chinese Participants | 2026-11 |
| NCT07915011Haisco Pharmaceutical Group Co., Ltd.Investigation of Pharmacokinetics, Safety of HSK31858 in Subjects With Renal Impairment | 2026-11 |
| NCT07913009Haisco Pharmaceutical Group Co., Ltd.Investigation of Pharmacokinetics, Safety of HSK31858 in Subjects With Hepatic Impairment | 2026-12 |
Add all 15 to your calendar (.ics) → With an account.
Among the 84 studies in Bronchiectasis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.
AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.
This Phase II study aims to assess the efficacy, safety, and PK of AZD0292 administered IV, as compared to placebo in participants 18 years of age and older.
The population of this study will be Chinese NCFBE patients with frequent pulmonary exacerbations due to chronic PsA airway colonization. These PsA associated pulmonary exacerbations contribute to a decline in lung function, impair quality of life and increase mortality, highlighting the urgent need for effective therapeutic options.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AZD0292 administered starting on Day 1, subsequent administrations per schedule of assessments.
Drug: AZD0292
Placebo administered starting on Day 1, subsequent administrations per schedule of assessments.
Other: Placebo
AZD0292 administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments.
Placebo administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments.
Annualized rate of exacerbations over a variable follow-up time
To evaluate the effect of IV AZD0292 compared to placebo on the rate of moderate-to severe pulmonary exacerbations in participants with NCFBE and chronic colonization with PsA
Time frame: Min 28 weeks, max 52 weeks
Annualized rate of severe exacerbations over a variable follow-up time
To evaluate the effect of AZD0292 compared to placebo on severe exacerbations in participants with NCFBE and chronic colonization with PsA
Time frame: Min 28 weeks, max 52 weeks
Change from baseline in QoL-B-RSS
To evaluate the effect of AZD0292 compared to placebo on quality of life, as assessed by QoL-B-RSS over the observation period
Time frame: Over the observation period (Week 0 to Last Dose+4 weeks)
Change from baseline in SGRQ score
To evaluate the effect of AZD0292 compared to placebo on quality of life, as assessed by SGRQ over the observation period.
Time frame: Over the observation period (Week 0 to Last Dose+4 weeks)
Time to first moderate or severe exacerbation
To evaluate the effect of AZD0292 compared to placebo on time to first pulmonary exacerbation in participants with NCFBE and chronic colonization with PsA.
Time frame: Time Frame: Through study completion (Final Dose +24 weeks)
Serum Concentrations
To evaluate AZD0292 serum concentrations following IV dosing in participants with bronchiectasis and chronic colonization with PsA
Time frame: At specified timepoints between Week 0 and Final Dose +12 weeks
Incidence of ADA and ADA titers to AZD0292
To evaluate the immunogenicity of IV doses of AZD0292 in participants with bronchiectasis and chronic colonization with PsA
Time frame: At specified timepoints between Week 0 and Final Dose +12 weeks
Incidence of AEs, SAEs, AESIs and MAAEs
To assess the safety of AZD0292 compared with placebo in participants with bronchiectasis and chronic colonization with PsA
Time frame: Occurrence of AEs; first dose through 12 weeks after last study intervention administration. Occurrence of SAEs, AESIs, and MAAEs; through study completion (Final Dose+24 weeks)
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Jan 2028, 18 months after the start.
Of 24 phase 2 interventional studies under Bronchiectasis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's planned 18 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD0292